0001209191-22-045296.txt : 20220810
0001209191-22-045296.hdr.sgml : 20220810
20220810181351
ACCESSION NUMBER: 0001209191-22-045296
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220808
FILED AS OF DATE: 20220810
DATE AS OF CHANGE: 20220810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ostertag Eric
CENTRAL INDEX KEY: 0001765987
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39376
FILM NUMBER: 221153059
MAIL ADDRESS:
STREET 1: C/O POSEIDA THERAPEUTICS, INC.
STREET 2: 4242 CAMPUS POINT COURT, SUITE 700
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Poseida Therapeutics, Inc.
CENTRAL INDEX KEY: 0001661460
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 472846548
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-779-3100
MAIL ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-08
0
0001661460
Poseida Therapeutics, Inc.
PSTX
0001765987
Ostertag Eric
C/O POSEIDA THERAPEUTICS, INC.
9390 TOWNE CENTRE DRIVE, STE 200
SAN DIEGO
CA
92121
1
1
1
0
Executive Chairman
Common Stock
2022-08-08
4
P
0
142857
3.50
A
838824
D
Common Stock
3659503
I
See footnote
Common Stock
3358455
I
See footnote
Common Stock
580292
I
See footnote
Common Stock
961445
I
See footnote
This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with sales effected on August 3, 2022 pursuant to a Rule 10b5-1 trading plan established independently of the reporting person by Transposagen Biopharmaceuticals and in connection with a planned dissolution of Transposagen Biopharmaceuticals. The reporting person will disgorge the full amount of any recoverable profits to the Issuer.
The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
/s/ Harry J. Leonhardt, Attorney-in-Fact
2022-08-10